menu
    • menu
    [{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"||GABR","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Undisclosed"},{"orgOrder":0,"company":"NextCell Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Wharton\\'S Jelly Derived Allogenic Mesenchymal Stromal Cell","moa":"Immune","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"NextCell Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NextCell Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCell Pharma \/ Undisclosed"},{"orgOrder":0,"company":"NextCell Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"NextCell Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextCell Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NextCell Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Per-Ola Carlsson","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"GABR","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Per-Ola Carlsson","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Per-Ola Carlsson"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Diamyd Medical AB

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Diamyd Medical Reports that Clinical Trial with Remygen[®] is Expanded to Evaluate Prevention of Hypoglycaemi...

                            Details : The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.

                            Product Name : Remygen

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 24, 2020

                            Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Diamyd Medical AB

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GAD-alum

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Diamyd Medical receives Japanese patent for intralymphatic administration of diabetes vaccine Diamyd

                            Details : The patents protect the administration method of Diamyd® that is now being evaluated in the Phase IIb trial DIAGNODE-2, which previously showed positive results in the Phase I/II trial DIAGNODE-1.

                            Product Name : Diamyd

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 27, 2020

                            Lead Product(s) : GAD-alum

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NextCell Pharma

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed

                            NextCell Pharma

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Wharton\'S Jelly Derived Allogenic Mesenchymal Stromal Cell

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I...

                            Details : Wharton'S Jelly Derived Allogenic Mesenchymal Stromal Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 04, 2019

                            Lead Product(s) : Wharton\'S Jelly Derived Allogenic Mesenchymal Stromal Cell

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Diamyd Medical AB

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Per-Ola Carlsson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Di...

                            Details : Gamma-Aminobutyric Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 17, 2018

                            Lead Product(s) : Gamma-Aminobutyric Acid

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Per-Ola Carlsson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NextCell Pharma

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed

                            NextCell Pharma

                            Sweden arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Mesenchymal Stromal Cell

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes

                            Details : Allogeneic Mesenchymal Stromal Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 23, 2018

                            Lead Product(s) : Allogeneic Mesenchymal Stromal Cell

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth